Dr. Kelly is a gastroenterologist at The Brigham and Women’s Hospital, and member of the faculty in the Department of Medicine at Harvard Medical School. She graduated from The Ohio State University College of Medicine, and completed residency in internal medicine at Boston Medical Center and GI fellowship at the Rhode Island Hospital/Brown program, where she held her previous faculty position as an Associate Professor of Medicine.

The focus of Dr. Kelly’s research and clinical practice is Clostridioides difficile infection (CDI) and fecal microbiota transplantation (FMT). She was the principal investigator (PI) for the first placebo-controlled trial of FMT for treatment of recurrent CDI and one of the first investigators to sponsor of an investigational new drug application for FMT with the FDA, and has served on working groups around regulatory issues related to microbiota-based therapies. Dr. Kelly has been involved in clinical  trials of live biotherapeutic products and collaborated on studies looking at FMT in patients with inflammatory bowel disease. She is interested in the long-term effects around manipulation of gut microbiota and is a principal investigator for the NIH-funded FMT National Patient Registry, which will answer important questions around real-world effectiveness and safety. In addition to coauthoring current FMT guidelines and participating in drafting the European Consensus Conference on FMT in Clinical Practice, she was the lead author for the American College of Gastroenterology 2021 CDI treatment guidelines. Dr. Kelly is a Fellow of the ACG, and a Fellow and past member of the scientific advisory board for Gut Microbiome Research and Education of the American Gastroenterological Association.